Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects. Rosenson RS, Tate A, Mar P, Grushko O, et al. Atherosclerosis 2024;392:117529.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rosenson RS, Tate A, Mar P, Grushko O, et al. Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects. Atherosclerosis 2024;392:117529.
PMID: 38583289